Evidence map›Paper›PMID 37907352›Full record

ArticleMolecular pharmacology2023

A

Jesús Giraldo, Jesper J Madsen, Xudong Wang, Lei Wang, Cheng Zhang, Libin Ye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jesús GiraldoLaboratory of Molecular Neuropharmacology and Bioinformatics, Unitat de Bioestadística and Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Bellaterra, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (J.G.), CIBERSAM, Spain; Unitat de Neurociència Traslacional, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Spain; Global and Planetary Health, College of Public Health (J.J.M.), Center for Global Health and Infectious Diseases Research, College of Public Health (J.J.M.), Department of Molecular Medicine, Morsani College of Medicine (J.J.M.), Department of Molecular Biosciences (X.W., L.Y.), University of South Florida, Tampa, Florida; Department of Pharmacology and Chemical Biology, University of PittsburghSchool of Medicine (L.W., C.Z.), University of Pittsburgh, Pittsburgh, Pennsylvania; and Lee Moffitt Cancer Center & Research Institute, Tampa, Florida (L.Y.) Jesus.Giraldo@uab.es libinye@usf.edu.ORCID 0000-0001-7082-4695
Jesper J MadsenLaboratory of Molecular Neuropharmacology and Bioinformatics, Unitat de Bioestadística and Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Bellaterra, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (J.G.), CIBERSAM, Spain; Unitat de Neurociència Traslacional, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Spain; Global and Planetary Health, College of Public Health (J.J.M.), Center for Global Health and Infectious Diseases Research, College of Public Health (J.J.M.), Department of Molecular Medicine, Morsani College of Medicine (J.J.M.), Department of Molecular Biosciences (X.W., L.Y.), University of South Florida, Tampa, Florida; Department of Pharmacology and Chemical Biology, University of PittsburghSchool of Medicine (L.W., C.Z.), University of Pittsburgh, Pittsburgh, Pennsylvania; and Lee Moffitt Cancer Center & Research Institute, Tampa, Florida (L.Y.).ORCID 0000-0003-1411-9080
Xudong WangLaboratory of Molecular Neuropharmacology and Bioinformatics, Unitat de Bioestadística and Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Bellaterra, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (J.G.), CIBERSAM, Spain; Unitat de Neurociència Traslacional, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Spain; Global and Planetary Health, College of Public Health (J.J.M.), Center for Global Health and Infectious Diseases Research, College of Public Health (J.J.M.), Department of Molecular Medicine, Morsani College of Medicine (J.J.M.), Department of Molecular Biosciences (X.W., L.Y.), University of South Florida, Tampa, Florida; Department of Pharmacology and Chemical Biology, University of PittsburghSchool of Medicine (L.W., C.Z.), University of Pittsburgh, Pittsburgh, Pennsylvania; and Lee Moffitt Cancer Center & Research Institute, Tampa, Florida (L.Y.).
Lei WangLaboratory of Molecular Neuropharmacology and Bioinformatics, Unitat de Bioestadística and Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Bellaterra, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (J.G.), CIBERSAM, Spain; Unitat de Neurociència Traslacional, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Spain; Global and Planetary Health, College of Public Health (J.J.M.), Center for Global Health and Infectious Diseases Research, College of Public Health (J.J.M.), Department of Molecular Medicine, Morsani College of Medicine (J.J.M.), Department of Molecular Biosciences (X.W., L.Y.), University of South Florida, Tampa, Florida; Department of Pharmacology and Chemical Biology, University of PittsburghSchool of Medicine (L.W., C.Z.), University of Pittsburgh, Pittsburgh, Pennsylvania; and Lee Moffitt Cancer Center & Research Institute, Tampa, Florida (L.Y.).
Cheng ZhangLaboratory of Molecular Neuropharmacology and Bioinformatics, Unitat de Bioestadística and Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Bellaterra, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (J.G.), CIBERSAM, Spain; Unitat de Neurociència Traslacional, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Spain; Global and Planetary Health, College of Public Health (J.J.M.), Center for Global Health and Infectious Diseases Research, College of Public Health (J.J.M.), Department of Molecular Medicine, Morsani College of Medicine (J.J.M.), Department of Molecular Biosciences (X.W., L.Y.), University of South Florida, Tampa, Florida; Department of Pharmacology and Chemical Biology, University of PittsburghSchool of Medicine (L.W., C.Z.), University of Pittsburgh, Pittsburgh, Pennsylvania; and Lee Moffitt Cancer Center & Research Institute, Tampa, Florida (L.Y.).
Libin YeLaboratory of Molecular Neuropharmacology and Bioinformatics, Unitat de Bioestadística and Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Bellaterra, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (J.G.), CIBERSAM, Spain; Unitat de Neurociència Traslacional, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Institut de Neurociències, Universitat Autònoma de Barcelona (J.G.), Spain; Global and Planetary Health, College of Public Health (J.J.M.), Center for Global Health and Infectious Diseases Research, College of Public Health (J.J.M.), Department of Molecular Medicine, Morsani College of Medicine (J.J.M.), Department of Molecular Biosciences (X.W., L.Y.), University of South Florida, Tampa, Florida; Department of Pharmacology and Chemical Biology, University of PittsburghSchool of Medicine (L.W., C.Z.), University of Pittsburgh, Pittsburgh, Pennsylvania; and Lee Moffitt Cancer Center & Research Institute, Tampa, Florida (L.Y.) Jesus.Giraldo@uab.es libinye@usf.edu.ORCID 0000-0003-0818-2972

Funding

Structure, pharmacology and signaling of G protein-coupled receptors (GPCRs) in inflammationR35GM128641 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHENG ZHANG · 2018 to 2026
$3.5M
The Role of Intermediate Conformations in G Protein-coupled Receptor SignalingR01GM149659 · NIGMS · UNIVERSITY OF SOUTH FLORIDA · PI Libin Ye · 2023 to 2026
$1.4M
NIGMS NIH HHS R01 GM149659NIGMS NIH HHS R35 GM128641
6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs) exhibit a wide range of pharmacological efficacies, yet the molecular mechanisms responsible for the differential efficacies in response to various ligands remain poorly understood. This lack of understanding has hindered the development of a solid foundation for establishing a mathematical model for signaling efficacy. However, recent progress has been made in delineating and quantifying receptor conformational states and associating function with these conformations. This progress has allowed us to construct a mathematical model for GPCR signaling efficacy that goes beyond the traditional ON/OFF binary switch model. In this study, we present a quantitative conformation-based mathematical model for GPCR signaling efficacy using the adenosine A

Indexed as

NucleotidesReceptors, G-Protein-CoupledLigandsModels, MolecularProtein ConformationLigandsNucleotidesReceptors, G-Protein-Coupled

Identifiers

PMID37907352
PMCPMC10739436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.